Member Info for Titania

"1. Patient stratification or endotyping approaches
a. DRIVe is interested in validating stratification approaches and technologies that can aid in improved patient management or therapeutic intervention for infectious disease. Evidence suggests that common clinical characteristics or biomarkers can be used to predict patient trajectory and outcomes in order to aid in clinical management as well as to identification of patient subpopulation likely to benefit from a particular therapeutic. Potential ses of interest, include but are not limited to: clinical trial enrichment strategy, support clinical decision-making for an individual patient; and companion diagnostic to inform on therapeutic intervention. Of interest are approaches or technologies, based on individual patient characteristics, including host biomarkers, clinical data, physiological or vital sign data, or other information that can be utilized to inform on patient stratification."

https://drive.hhs.gov/files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_01.pdf

Seems to be no information on how long on average patients had Covid symptoms for. All we know is it wasn't for longer than 3 weeks?

Sng001 seems to be associated with low pulmonary embolism and respiratory distress!
Adverse events
SNG001 Placebo
Pulmonary embolism * 1 0/301 (0.00%) 0 5/303 (1.65%) 5
Respiratory distress * 1 0/301 (0.00%) 0 2/303 (0.66%) 2

Is this research what led Janssen to Synairgen.

"Janssen, in collaboration with Rega Institute of Medical Research, will screen libraries to identify therapeutic compounds with antiviral activity against 2019-nCoV."

Base Award Amount $152,312,126

https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx?
filter=therapeutic

Astra Zeneca and Johnson&Johnson on leadership organisations list.
https://www.nih.gov/research-training/medical-research-initiatives/activ#organizations

We seem to be using Link Market Services for something now. A virtual meeting maybe?

https://www.synairgen.com/investors/advisers

From memory I think it used to just say she advised Synairgen but now talks about Synairgen Research as well.

https://www.keystonelaw.com/lawyers/claire-blewett

9.1 Influenza Antiviral Therapeutics
9.3 Immunomodulators or therapeutics targeting lung repair
9.6 Pre-exposure Prophylaxis – Influenza
9.7 Implementation of Phase 2 platform clinical trial for ARDS therapeutics

https://www.medicalcountermeasures.gov/barda/barda-baa

https://www.defenseworld.net/2023/03/03/synairgen-lonsng-shares-pass-below-two-hundred-day-moving-average-of-17-35.html

Article in US portal Defense World? Is Rick Bright helping with this exposure?

https://www.southampton.ac.uk/ctu/about/sctu-vacancies.page

"Each protocol, either adaptive or pragmatic, was designed to efficiently select those treatments that provide benefit to patients while rapidly eliminating those that were either not effective or safe."

https://www.healthcare.scientexconference.com/speakers/Stacey-J-Adam

https://www.japantimes.co.jp/news/2023/02/27/business/corporate-business/shionogi-covid-pill-sales-us-approval/

https://mobile.twitter.com/Synairgenplc/with_replies

"Janssen, in collaboration with Rega Institute of Medical Research, will screen libraries to identify therapeutic compounds with antiviral activity against 2019-nCoV."

https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx?filter=therapeutic

https://www.news-medical.net/news/20230221/Researchers-report-the-circulation-of-a-novel-MERS-like-coronavirus-in-Malayan-pangolins.aspx

He used to be very vocal before a TR1 but not recently!

Surely PM would have worked this out already?

Also Sprinter trial had a per protocol death rate of 2.7% within 35 days. Also within the 3% expected high viral rebound rate.